key: cord-0741559-7e2f863k authors: Carlo Iorio, Giuseppe; Ricardi, Umberto; Franco, Pierfrancesco title: The importance of IL-6 blockade beyond the COVID-19 pandemic: consideration for cancer care date: 2020-07-13 journal: Radiother Oncol DOI: 10.1016/j.radonc.2020.07.018 sha: c7bc7749619665a9dc5f8235c6030e861dc01e52 doc_id: 741559 cord_uid: 7e2f863k nan The novel human Coronavirus (SARS-CoV-2), which outbroke in Wuhan (China) in late 2019, is now responsible for the pandemic diffusion of COVID-19 [1] [2] [3] . Researchers are working on the validation of effective protocols, including antiviral therapies and vaccines [4] . Case-fatality rate seems correlated with virally-driven hyperinflammation [4, 5] . In this sense, recent data suggest a crucial role for cytokines release syndrome (CRS) and human interleukin-6 (IL-6) levels as fatality predictors [4, 5] . In this regard, tocilizumab, an IL-6 receptor inhibitor, is currently under investigation for patients with severe COVID-19 and elevated IL-6 levels, in order to counteract the proinflammatory CRS. Randomised trials have been approved in China and Europe to explore this hypothesis [6, 7] . Blocking IL-6 has been proved beneficial in inflammatory diseases, as rheumatoid arthritis [8] . Nevertheless, elevated levels of IL-6 may also play a role in cancer [9] . With respect to cancer pathogenesis, overexpressed IL-6 stimulates the JAK/STAT3 signaling hyperactivation, often associated with poor patients' outcomes [9] . The aberrant hyperactivation of the IL-6/JAK/STAT3 pathway impacts on tumor microenvironment via two mechanisms: o acting as a driver of tumor cell proliferation and scattering capacity o suppressing the antitumor immune-response [9] . Specifically, STAT3 hyperactivation has been linked with chemotherapy and radiotherapy (RT) resistance, given its critical role in the interaction between tumor-associated macrophages and tumor cells [10] . Thus, targeting IL-6 may enhance tumor control [9] . The relation between IL-6 and RT has been investigated in head and neck cancer (HNC) [10, 11] . Interestingly, in a series of 26 HNC patients, serum levels of pro-inflammatory markers, as IL-6, were found to be increased after RT and chemo-radiotherapy [11] . Thus, paradoxically, cancer treatments may favor a tumor-promoting pro-inflammatory microenvironment [11] . Accordingly, Matsuoka et al. hypothesized improved treatment response and survival in oral squamous cell carcinoma patients, when adding tocilizumab to RT, given its capacity to limit the IL-6 effect in reducing radiation-induced DNA damage [10] . The potential beneficial synergism on tumor microenvironment when combining RT and IL-6 blockade is being currently explored in specific oncological settings, as in pretreated advanced pancreatic cancer (PC) [12] . Patients enrolled within the Danish phase II TRIPPLE-R trial are planned to receive a 15 Gy single fraction of stereotactic body RT (SBRT), nivolumab, ipilimumab and tocilizumab [12] . The rationale is based on preclinical data showing that PC may act via multiple immune-evasion patterns [13] . Therefore, immune-checkpoint inhibitors combination is proposed to overcome the tumor "immuneescape" mechanism to potentially improve outcomes [12] . The addition of tocilizumab is aimed at limiting cancer progression, by counteracting the hyperactivation of the IL-6/JAK/STAT3 pathway [9] . As an immunological adjuvant strategy to increase antigen-release, patients will receive SBRT [12, 14] . Of interest, the same 3-drug combination is being evaluated within an ongoing phase II trial enrolling unresectable stage III-IV melanoma patients [15] . To conclude, this pandemic highlighted the importance of the IL-6 pathway within the CRS, observed during severe COVID-19. This led the Scientific Community to focus on the IL-6 blockade clinical potential. Since IL-6 is overexpressed in different cancers, promoting tumor progression, the present times may represent a boost to further investigate the combination of radiotherapy and therapies targeting the IL-6 pathway. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 COVID-19 outbreak and cancer radiotherapy disruption in italy: Survey endorsed by the italian association of radiotherapy and clinical oncology (AIRO) Radiation therapy during the coronavirus disease 2019 (covid-19) pandemic in Italy: a view of the nation's young oncologists COVID-19: consider cytokine storm syndromes and immunosuppression Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China Chinese Clinical Trial Registry. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19) Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia Interleukin-6 as a Therapeutic Target Targeting the IL-6/JAK/STAT3 signalling axis in cancer IL-6 controls resistance to radiation by suppressing oxidative stress via the Nrf2-antioxidant pathway in oral squamous cell carcinoma Radiotherapy and radiochemotherapy increase serum levels of pro-inflammatory interleukin-6 and C-reactive protein in patients with head and neck cancers Phase 2 Study in Pretreated Patients With Advanced Pancreatic Cancer to Assess Efficacy of Ipilimumab, Nivolumab and Tocilizumab in Combination With Radiation Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features Radiation as an immunological adjuvant: current evidence on dose and fractionation A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma. ClinicalTrials.gov Identifier None. No.